DeepMed Research

NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment

Phase 1

Recruiting

Conditions: MGMT-Methylated Glioblastoma
Recurrent Glioblastoma, IDH-Wildtype
Recurrent MGMT-Methylated Glioblastoma

Interventions: Procedure: Biospecimen Collection
Procedure: Magnetic Resonance Imaging
Drug: Temozolomide
Drug: Selinexor

First Posted Date: 2022-06-27

Last Posted Date: 2025-05-07

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 97

Registration Number: NCT05432804

Locations: 🇺🇸
Mayo Clinic Hospital in Arizona, Phoenix, Arizona, United States
🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸
UC San Diego Moores Cancer Center, La Jolla, California, United States

and more 33 locations

Testing Olaparib and Temozolomide Versus the Usual Treatment for Uterine Leiomyosarcoma After Chemotherapy Has Stopped Working

Phase 2

Active, not recruiting

Conditions: Locally Advanced Uterine Corpus Leiomyosarcoma
Stage IV Uterine Corpus Leiomyosarcoma AJCC v8
Stage III Uterine Corpus Leiomyosarcoma AJCC v8
Metastatic Uterine Corpus Leiomyosarcoma
Unresectable Uterine Corpus Leiomyosarcoma

Interventions: Procedure: Biospecimen Collection
Procedure: Bone Scan
Procedure: Computed Tomography
Procedure: Magnetic Resonance Imaging
Procedure: Multigated Acquisition Scan
Drug: Olaparib
Drug: Pazopanib
Drug: Temozolomide
Drug: Trabectedin
Procedure: Transthoracic Echocardiography Test

First Posted Date: 2022-06-27

Last Posted Date: 2025-04-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 190

Registration Number: NCT05432791

Locations: 🇺🇸
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
🇺🇸
Alaska Women's Cancer Care, Anchorage, Alaska, United States
🇺🇸
Mayo Clinic Hospital in Arizona, Phoenix, Arizona, United States

and more 142 locations

Omics of Cancer: OncoGenomics

Withdrawn

Conditions: Neoplasms
Cancer

First Posted Date: 2022-06-24

Last Posted Date: 2023-09-29

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT05431439

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer

Phase 1

Recruiting

Conditions: Anatomic Stage III Breast Cancer AJCC v8
Unresectable Triple-Negative Breast Carcinoma
Anatomic Stage IV Breast Cancer AJCC v8
Metastatic Triple-Negative Breast Carcinoma
Locally Advanced Triple-Negative Breast Carcinoma

Interventions: Drug: BET Bromodomain Inhibitor ZEN-3694
Procedure: Biospecimen Collection
Procedure: Biopsy Procedure
Procedure: Computed Tomography
Procedure: Magnetic Resonance Imaging
Drug: Nab-paclitaxel
Biological: Pembrolizumab

First Posted Date: 2022-06-21

Last Posted Date: 2025-05-16

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 57

Registration Number: NCT05422794

Locations: 🇺🇸
Boston Medical Center, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

and more 1 locations

Natural History of Pregnancy and Pregnancy Outcomes in Metreleptin-Treated vs Untreated Subjects With Lipodystrophy

Recruiting

Conditions: Lipodystrophy

First Posted Date: 2022-06-15

Last Posted Date: 2025-03-20

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 90

Registration Number: NCT05419037

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Imaging and Biopsy of People With HIV-1 Undergoing Analytic Treatment Interruption

Phase 2

Recruiting

Conditions: HIV

Interventions: Other: Acute Treatment Interruption

First Posted Date: 2022-06-15

Last Posted Date: 2025-05-08

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 50

Registration Number: NCT05419024

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Testing a Combination of Vaccines for Cancer Prevention in Lynch Syndrome

Phase 2

Recruiting

Conditions: Colorectal Carcinoma
Colorectal Neoplasm
Lynch Syndrome

Interventions: Biological: Adenovirus 5 CEA/MUC1/Brachyury Vaccine Tri-Ad5
Procedure: Biopsy Procedure
Procedure: Biospecimen Collection
Procedure: Colonoscopy
Drug: Placebo Administration
Drug: Nogapendekin Alfa
Other: Questionnaire Administration

First Posted Date: 2022-06-15

Last Posted Date: 2025-05-20

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 186

Registration Number: NCT05419011

Locations: 🇺🇸
Mayo Clinic Hospital in Arizona, Phoenix, Arizona, United States
🇺🇸
University of Arizona Cancer Center - Prevention Research Clinic, Tucson, Arizona, United States
🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States

and more 13 locations

Abemaciclib Neuropharmacokinetics of Diffuse Midline Glioma Using Intratumoral Microdialysis

Phase 1

Recruiting

Conditions: Glioma

Interventions: Drug: pre-operative abemaciclib
Device: Device for Cerebral Fluid Dialysate Collection
Device: Ashion Analytics GEM ExTra
Drug: abemaciclib + temozolomide

First Posted Date: 2022-06-10

Last Posted Date: 2025-05-20

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 17

Registration Number: NCT05413304

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Oral Iloprost for the Prevention of Lung Cancer In Former Smokers

Phase 2

Withdrawn

Conditions: Chronic Obstructive Pulmonary Disease
Lung Carcinoma
Bronchial Epithelial Dysplasia
Stage I Lung Cancer AJCC v8
Stage II Lung Cancer AJCC v8
Tobacco-Related Carcinoma

Interventions: Procedure: Biospecimen Collection
Procedure: Bronchial Brush Biopsy
Procedure: Bronchoscopy
Drug: Placebo Administration
Drug: Iloprost
Other: Questionnaire Administration

First Posted Date: 2022-06-09

Last Posted Date: 2024-05-17

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT05411107

Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer

Phase 1

Recruiting

Conditions: Stage III Pancreatic Cancer AJCC v8
Locally Advanced Pancreatic Carcinoma
Stage II Pancreatic Cancer AJCC v8
Unresectable Pancreatic Carcinoma

Interventions: Procedure: Biopsy Procedure
Procedure: Biospecimen Collection
Biological: Durvalumab
Drug: Olaparib
Radiation: Radiation Therapy
Procedure: Radiologic Examination

First Posted Date: 2022-06-09

Last Posted Date: 2025-04-09

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 18

Registration Number: NCT05411094

Locations: 🇺🇸
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine, California, United States
🇺🇸
Los Angeles General Medical Center, Los Angeles, California, United States
🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States

and more 8 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy